A prospective, multicenter study found that a blood-based miRNA assay combined with CA19-9 improved early detection of pancreatic ductal adenocarcinoma.
|Articles|September 1, 2000
Oncology NEWS International
- Oncology NEWS International Vol 9 No 9
- Volume 9
- Issue 9
PRIMATOM System Combines CT Scanning With Radiation Therapy
CONCORD, Calif-Siemens Oncology Care Systems Group has unveiled the PRIMATOM System, which combines a CT scanner with a linear accelerator for radiation therapy. The machine is currently in use at the Carol G. Simon Cancer Center at Atlantic Health System’s Morristown Memorial Hospital, New Jersey.
Advertisement
CONCORD, CalifSiemens Oncology Care Systems Group has unveiled the PRIMATOM System, which combines a CT scanner with a linear accelerator for radiation therapy. The machine is currently in use at the Carol G. Simon Cancer Center at Atlantic Health Systems Morristown Memorial Hospital, New Jersey.
The PRIMATOM System consists of a Siemens CT scanner on a sliding gantry combined with a PRIMUS Linear Accelerator (see Figure). The technology provides oncologists for the first time with accurate, almost real-time diagnostic-quality images of tumors within the treatment room, the company said in a news release. It allows the patient to remain on one table while the tumor is pinpointed and treatment is delivered, said James Wong, MD, of Morristown.
Articles in this issue
about 26 years ago
Soy’s Effect on Breast Cancer Remains Uncertainabout 26 years ago
STAR Enrollment Tops 6,000 in First Year of Recruitmentabout 26 years ago
New rhTPO Being Tested in Three Trialsabout 26 years ago
New Research Centers Target How Market Forces Affect Health Careabout 26 years ago
Aromatase Inhibitors Actively Studied in Hormone-Dependent Breast Cancerabout 26 years ago
Tobacco Boosts In-Store AdvertisingAdvertisement
Related to this article
Final 5-year IMCgp100-202 data show tebentafusp improved OS vs investigator’s choice in untreated HLA-A*02:01–positive metastatic uveal melanoma.
The FDA granted platform technology designation to the immunotherapeutic platform for use in HPV-positive cancers such as head and neck, cervical, and anal.
An end-of-phase 1 meeting was supported by phase 1b data showing efficacy with LYT-220 among relapsed/refractory myelodysplastic syndrome groups.
Beth Erickson, MD, FACR, FASTRO, FABS, discussed pioneering MRI-guided brachytherapy at MCW and her priorities as incoming ASTRO president-elect.
The updated NCCN Guidelines for myeloproliferative neoplasms recommend rusfertide as a category 1 option across both low- and high-risk polycythemia vera.
As part of the ANDA pathway, Bravnetsa is the only radiopharmaceutical the FDA has determined to be bioequivalent and therapeutically equivalent to the reference product, Lutathera.
Xiuning Le, MD, PhD, explains how oncologists should approach HER2 biomarker testing following sevabertinib’s frontline approval in non–small cell lung cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Lutetium Lu 177 Dotatate Biosimilar Earns Final FDA Approval in GEP-NETs
2
Neoantigen Vaccine Shows Encouraging Activity in Head and Neck Cancer
3
Using Intrathecal Dendritic Cells for Leptomeningeal Disease From Breast Cancer
4
COA Warns That Price Negotiation for Medicare Part B Drugs Threatens Community Oncology
5